Melanotan II vs PT-141
Melanocortin agonist with tanning and sexual effects vs selective melanocortin-based sexual function peptide — parent compound vs refined derivative.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Melanotan II | PT-141 |
|---|---|---|
| Drug Class | Non-selective melanocortin agonist (MC1-5R) | Selective MC3R/MC4R agonist (Bremelanotide) |
| Primary Use | Skin tanning + sexual function | Female hypoactive sexual desire disorder (HSDD) |
| Administration | SC injection | SC injection (Vyleesi autoinjector) |
| Approval Status | Not approved; research peptide | FDA approved (Vyleesi, 2019) |
| Tanning Effect | Yes — strong MC1R-mediated melanogenesis | Minimal — reduced MC1R activity |
| Sexual Function | Yes — MC4R activation (both sexes) | Yes — MC4R activation (approved for women) |
| Nausea Risk | Common (~30%) | Common (~40%) |
| Key Concern | Unregulated; mole darkening; cardiovascular effects | Blood pressure elevation; max 8 doses/month |
Mechanism of Action
Melanotan II
Melanotan II Mechanism:
Melanotan II is a cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) that activates multiple melanocortin receptors non-selectively:
1. **MC1R** — Stimulates melanogenesis (skin darkening/tanning) 2. **MC3R** — Modulates energy homeostasis and sexual behaviour 3. **MC4R** — Central appetite suppression and sexual arousal 4. **MC5R** — Exocrine gland function
Developed at the University of Arizona, Melanotan II's broad receptor profile produces multiple effects simultaneously: tanning, sexual arousal, appetite suppression, and nausea. The non-selective nature is both its appeal (multiple effects) and its limitation (unpredictable side effect profile).
PT-141
PT-141 (Bremelanotide) Mechanism:
PT-141 is a metabolite of Melanotan II, refined to be more selective for MC3R and MC4R with reduced MC1R activity.
Key actions: 1. **MC4R activation** — Primary driver of sexual arousal response in the CNS 2. **MC3R activation** — Modulates sexual motivation and energy homeostasis 3. **Reduced MC1R activity** — Minimal tanning effect compared to Melanotan II
PT-141 works centrally — activating sexual arousal pathways in the hypothalamus rather than acting peripherally on blood vessels (like PDE5 inhibitors). This makes it effective regardless of the vascular or hormonal status of the patient.
Approved as Vyleesi in 2019 for premenopausal HSDD — the first melanocortin-based drug approved for sexual dysfunction.
Clinical Trial Evidence
Melanotan II Clinical Studies
Participants: 65
Duration: 5 days
Significant increase in skin melanin density after SC Melanotan II without UV exposure. Dose-dependent tanning observed.
Statistically significant
Participants: 10
Duration: Single dose
80% of men experienced erections after Melanotan II injection in controlled setting. Onset within 1-2 hours.
Statistically significant
Participants: 28
Duration: 10 days
Consistent melanogenesis at 0.025mg/kg. Side effects: nausea (30%), facial flushing (25%), fatigue. Tanning persisted weeks after cessation.
Statistically significant
Participants: 20
Duration: 7 days
Reduced caloric intake by ~10-15% during Melanotan II administration via MC4R-mediated appetite suppression.
Not statistically significant
Participants: 12
Duration: Variable
Reports of mole darkening, new mole formation, and rare melanoma concern in regular users. Established safety monitoring need.
Not statistically significant
PT-141 Clinical Studies
Participants: 1247
Duration: 24 weeks
Significant increase in satisfying sexual events (+0.5 vs +0.2 placebo) and desire scores. Approved by FDA.
Statistically significant
Participants: 287
Duration: 1 month (at-home)
59% of ED patients had successful intercourse with PT-141 vs 44% placebo. Effective in PDE5 inhibitor non-responders.
Statistically significant
Participants: 327
Duration: 12 weeks
1.75mg SC dose identified as optimal. Significant improvement in FSFI desire domain and distress scores.
Statistically significant
Participants: 342
Duration: 3 months
Intranasal formulation showed efficacy in ED but was abandoned due to hypertension concerns with nasal dosing.
Not statistically significant
Participants: 1247
Duration: 24 weeks
Transient BP increase of 2-3 mmHg systolic post-injection. No serious cardiovascular events. Max 8 doses/month recommended.
Statistically significant
Benefits Comparison
Melanotan II Unique Benefits
- Skin tanning without UV exposure
- Sexual function enhancement (both sexes)
- Appetite suppression
- Long-lasting tanning effect
- Multi-purpose single compound
Shared Benefits
- Melanocortin receptor activation
- Sexual function enhancement
- Central mechanism of action (hypothalamic)
- Nausea as common side effect
PT-141 Unique Benefits
- FDA approved (Vyleesi) with clinical validation
- More selective receptor profile
- Effective in PDE5 inhibitor non-responders
- Works via central arousal (not vascular)
- Standardised dosing and safety monitoring
Research & Evidence
Melanotan II Research
Melanotan II has never completed the full regulatory approval process. Research is limited to early-phase studies and university research. The compound's non-selective profile made it unsuitable for pharmaceutical development in its native form. Most usage data comes from self-experimentation reports and harm-reduction surveys.
PT-141 Research
PT-141/Bremelanotide completed the full FDA approval pathway — Phase I through Phase III (RECONNECT trial, 1,247 women) and post-marketing requirements. The RECONNECT programme is the definitive evidence for melanocortin-based treatment of HSDD. Male ED studies showed promise but the programme was deprioritised after Vyleesi approval for women.
Head-to-Head Analysis
Relationship:
PT-141 was derived directly from Melanotan II during clinical development. When Melanotan II showed consistent pro-sexual effects, researchers isolated the metabolite responsible (PT-141/Bremelanotide) and developed it as a targeted sexual function drug.
Key Differences: - Melanotan II causes significant tanning; PT-141 has minimal melanogenic effect - Melanotan II has broader effects (appetite suppression, tanning, sexual function); PT-141 is more targeted - PT-141 achieved FDA approval; Melanotan II remains unregulated - Both cause nausea via central melanocortin activation
Regulatory Split: PT-141's development followed the pharmaceutical refinement model — taking a research compound with multiple effects and creating a more selective, approvable derivative. Melanotan II remains in the unregulated research peptide market, primarily used for tanning.
Protocol Comparison
Melanotan II Protocol
Melanotan II Theoretical Protocols (Research-Based):
Tanning Protocol (commonly cited): Loading: 0.25-0.5mg SC daily for 2-3 weeks Maintenance: 0.5mg 1-2x weekly Best combined with moderate UV exposure for optimal melanogenesis.
Sexual Function: Acute: 0.5-1.0mg SC, 1-2 hours before activity.
⚠️ Disclaimer: Melanotan II is not approved for any therapeutic use. Unregulated supply carries purity and contamination risks.
PT-141 Protocol
PT-141 (Vyleesi) Approved Protocol:
For HSDD (Premenopausal Women): 1.75mg SC (autoinjector) at least 45 minutes before anticipated sexual activity. Maximum: 1 dose per 24 hours, ≤8 doses per month.
Route: Subcutaneous — abdomen only (autoinjector).
Duration: As-needed use. Discontinue after 8 weeks if no improvement.
⚠️ Note: Prescription medication. Blood pressure monitoring recommended.
Safety Profiles
Melanotan II Safety
Melanotan II Safety Concerns:
Common: Nausea (30%), facial flushing (25%), fatigue, injection site reactions.
Serious concerns: - Mole changes — Darkening, new mole formation, potential masking of melanoma - Cardiovascular — Transient blood pressure changes reported - Unregulated supply — Purity, sterility, and dosing accuracy cannot be guaranteed - No post-marketing surveillance — True incidence of adverse events unknown
The EMA, TGA, and FDA have all issued warnings against Melanotan II use.
PT-141 Safety
PT-141 (Vyleesi) Safety Profile (FDA-Approved):
Common: Nausea (40%), flushing (20%), headache (11%), injection site reactions (5%).
Warnings: - Transient blood pressure increase (2-3 mmHg systolic) — resolve within 12 hours - Contraindicated in uncontrolled hypertension - Maximum 8 doses/month to limit cardiovascular exposure - Focal hyperpigmentation at injection sites (rare)
Post-marketing: No unexpected safety signals since 2019 approval.
The Verdict
PT-141 represents the pharmaceutical refinement of Melanotan II — more selective, FDA-approved, with a characterised safety profile. For sexual function, PT-141/Vyleesi is the evidence-based choice with standardised dosing and safety monitoring. Melanotan II remains popular in the unregulated market primarily for tanning, which PT-141 does not effectively provide. The choice between them often reflects the user's primary goal: tanning (Melanotan II, unregulated) vs sexual function (PT-141, approved).
Frequently Asked Questions
Conclusion
Melanotan II and PT-141 represent a parent-compound/derivative relationship — from broad-spectrum melanocortin agonism to targeted sexual function therapy. PT-141 achieved what Melanotan II could not: regulatory approval, standardised dosing, and characterised safety. For sexual dysfunction research, PT-141/Vyleesi is the validated option. Melanotan II's appeal in the unregulated market centres on its unique tanning effect, which PT-141 does not replicate. Both act through melanocortin receptors and share the common side effect of nausea. Medical supervision is essential for both.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Melanotan II nor PT-141 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.